Genetic testing is used to identify patients with chronic lymphocytic leukemia (CLL) who are poor candidates for conventional chemoimmunotherapy. H......READ MORE
by Susan O’Brien, MD; Jennifer R. Brown, MD, PhD; Bruce D. Cheson, MD, FACP, FAAAS, FASCO
The most useful outcome measures in chronic lymphocytic leukemia (CLL) are dependent on the treatment regimen. In general, progression-free surviva......READ MORE
by Jennifer R. Brown, MD, PhD, Bruce D. Cheson, MD, FACP, FAAAS, FASCO, Susan O’Brien, MD
With the emergence of novel agents for the treatment of chronic lymphocytic leukemia (CLL), the focus has shifted away from the concept of post-che......READ MORE
clinical topic updates by Jennifer R. Brown, MD, PhD, Bruce D. Cheson, MD, FACP, FAAAS, FASCO, Susan O’Brien, MD
Richter transformation (RT) represents a spectrum of disease that can involve progression to a number of hematologic diseases. Recent evidence sugg......READ MORE
Identifying patients with at-risk chronic lymphocytic leukemia (CLL) who are likely to have rapid progression to symptomatic disease is challenging......READ MORE
Clinicians who do not have extensive experience with novel therapies for chronic lymphocytic leukemia may question whether patients are responding ......READ MORE
